Management of allergic bronchopulmonary aspergillosis: a review and update

@article{Mahdavinia2012ManagementOA,
  title={Management of allergic bronchopulmonary aspergillosis: a review and update},
  author={Mahboobeh Mahdavinia and Leslie C. Grammer},
  journal={Therapeutic Advances in Respiratory Disease},
  year={2012},
  volume={6},
  pages={173 - 187}
}
Since the first description of allergic bronchopulmonary aspergillosis (ABPA) in the 1950s there have been numerous studies that have shed light on the characteristics and immunopathogenesis of this disease. The increased knowledge and awareness have resulted in earlier diagnosis and treatment of patients with this condition. This article aims to provide a summary and updates on ABPA by reviewing the results of recent studies on this disease with a focus on articles published within the last 5… 

Figures and Tables from this paper

Diagnosis of allergic bronchopulmonary aspergillosis: a case-based approach.

A case-based approach is utilized to elaborate on the diagnosis of allergic bronchopulmonary aspergillosis and intends to provide a lucid understanding of the diagnostic process for the expert as well as the primary physician, involved in management of this enigmatic disorder.

Allergic bronchopulmonary aspergillosis

  • A. Knutsen
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2015
It is suggested that ABPA might be underdiagnosed, as there remains lack of agreement on diagnostic criteria and approaches to treatment of patients with Allergic Bronchopulmonary Aspergillosis (ABPA).

Allergic Bronchopulmonary Aspergillosis

Treatment has long focused on downregulation of the inflammatory response with prolonged courses of oral glucocorticosteroids, but more recently concerns with steroid toxicity and availability of new treatment modalities has led to trials of oral azoles, inhaled amphotericin, pulse intravenous steroids, and subcutaneously-injected anti-IgE monoclonal antibody omalizumab, all of which show evidence of efficacy and reduced toxicity.

Laboratory biomarkers in the diagnosis and follow-up of treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.

The biomarkers included in these diagnostic criteria and novel research biomarkers that may be used in the diagnosis and treatment follow-up of ABPA in cystic fibrosis are reviewed.

Omalizumab Treatment for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis

Omalizumab may be an alternative therapy for ABPA in CF patients who fail to respond to systemic corticosteroids or have serious adverse effects, and this study showed steroid-sparing effect, decreasing IgE levels, and improvement in respiratory symptoms in 6 CF patients with omalIZumab treatment.

Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

  • R. AgarwalA. Chakrabarti D. Denning
  • Medicine, Biology
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2013
The importance of recognizing ABPA relates to the improvement of patient symptoms, and delay in development or prevention of bronchiectasis, one manifestation of permanent lung damage in ABPA.

Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis

With clinical deterioration of a patient with CF, ABPA is important to be kept in mind because clinical manifestations mimic pulmonary exacerbations of CF and early diagnosis and appropriate treatment are important in preventing complications related to ABPA.

Allergic bronchopulmonary aspergillosis: A clinical review of 24 patients: Are we right in frequent serologic monitoring?

ABPA is a disease with varied clinical, radiological, and serological patterns and further studies are required to simplify the diagnosis and treatment algorithms in resource-limited countries.

Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

Diagnosis of ABPA in CF patients should be sought in those with evidence of clinical and radiologic deterioration that is not attributable to another etiology, a markedly elevated total serum IgE level (while off steroid therapy) and evidence of A. fumigatus sensitization.

Case Report: Allergic Bronchopulmonary Aspergillosis Revealing Asthma

A case of ABPA in a woman without a known history of asthma, based on elevated eosinophil count, the presence of specific IgE and IgG against Aspergillus fumigatus and left segmental collapse on chest computed tomography, is reported.

References

SHOWING 1-10 OF 105 REFERENCES

Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies.

It is proposed that 13 patients with all serologic characteristics of ABPA but without central bronchiectasis have seropositive ABPA and represent the earliest cases of it that can be diagnosed in contrast with ABPA with central bronchopulmonary aspergillosis in which lung damage is already present.

Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients.

HAM impaction in ABPA is associated with initial serologic severity and frequent relapses but does not seem to influence complete remission.

Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis.

Clinical and immunologic characteristics are reported in a series of 20 patients with allergic bronchopulmonary aspergillosis seen by physicians in one consulting service during a period of 9 years, reflecting the increasing recognition of the entity.

[Allergic bronchopulmonary aspergillosis].

The problem of the possibility of the systemic pathoimmune manifestations associated with skin, eye and kidney injuries that occur during allergic bronchopulmonary aspergillosis is discussed.

Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.

There was a significant drop in IgE levels post treatment as well as a decrease in steroid dosing, and the improvement in FEV was not statistically significant; however there was a very wide variation in pre-treatment levels.

The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk.

Using both modern serologic criteria complete with a history of asthma and radiologic findings, the diagnosis of allergic bronchopulmonary aspergillosis was made in 28 of 100 consecutive patients with asthma who had immediate cutaneous reactivity to Aspergillus fumigatus and who were seen in an outpatient setting.

Stage V (fibrotic) allergic bronchopulmonary aspergillosis. A review of 17 cases followed from diagnosis.

A review of the records of 17 patients with stage V (fibrotic stage) allergic bronchopulmonary aspergillosis observed since initial diagnosis demonstrated that, of the 11 surviving patients, four have very severe respiratory impairment.

Allergic bronchopulmonary aspergillosis: A review of 42 patients from a tertiary care center in India

Objective: To study the clinical, radiological, and laboratory profile in patients of allergic bronchopulmonary aspergillosis (ABPA). Materials and Methods: Retrospective analysis of 42 cases of

Clinical aspects of allergic bronchopulmonary aspergillosis.

  • P. Greenberger
  • Medicine, Biology
    Frontiers in bioscience : a journal and virtual library
  • 2003
Allergic Bronchopulmonary Aspergillosis (ABPA) is characterized by recurrent pulmonary infiltrates that can result in central bronchiectasis and bronchiolitis obliterans especially if there is a lack

Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India.

There is a high prevalence of ABPA in asthmatic patients presenting at a chest clinic in India; the vast majority of patients have bronchiectasis at presentation, and almost half are initially misdiagnosed as having pulmonary tuberculosis.
...